Press Release Mar 09 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Nitroglycerin Sublingual Tablets. These tablets are used to relieve chest pain in patients with coronary artery disease and will be manufactured at the company's facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 08 2022
- Press Release Mar 07 2022
- Press Release Feb 23 2022
- Press Release Feb 14 2022
- Press Release Feb 02 2022
Later from Zydus Lifesciences
- Press Release Mar 14 2022
- Press Release Mar 21 2022
- Press Release Apr 01 2022
- Press Release Apr 13 2022
- Press Release Apr 18 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences